Bellevue Group AG Reduces Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Bellevue Group AG reduced its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 50.2% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 171,317 shares of the biotechnology company’s stock after selling 173,031 shares during the period. Bellevue Group AG’s holdings in Sarepta Therapeutics were worth $20,830,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in SRPT. Vanguard Group Inc. increased its holdings in Sarepta Therapeutics by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company’s stock worth $1,104,701,000 after acquiring an additional 117,904 shares during the last quarter. Capital International Investors increased its stake in shares of Sarepta Therapeutics by 38.9% in the fourth quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company’s stock worth $1,057,482,000 after purchasing an additional 2,437,855 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its position in shares of Sarepta Therapeutics by 0.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,956,583 shares of the biotechnology company’s stock valued at $237,901,000 after purchasing an additional 10,343 shares during the period. Geode Capital Management LLC lifted its stake in shares of Sarepta Therapeutics by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 1,706,353 shares of the biotechnology company’s stock valued at $207,538,000 after buying an additional 9,999 shares in the last quarter. Finally, Norges Bank bought a new position in Sarepta Therapeutics in the 4th quarter worth approximately $126,315,000. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Trading Up 1.2 %

Shares of SRPT stock opened at $63.51 on Friday. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The firm has a market cap of $6.24 billion, a P/E ratio of 50.81 and a beta of 0.93. The business has a 50-day moving average price of $72.86 and a two-hundred day moving average price of $103.55. Sarepta Therapeutics, Inc. has a 12-month low of $48.01 and a 12-month high of $173.25.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the transaction, the director now directly owns 27,812 shares of the company’s stock, valued at approximately $2,771,187.68. This trade represents a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 7.70% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft dropped their target price on Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating on the stock in a research report on Wednesday, March 19th. Morgan Stanley cut their target price on Sarepta Therapeutics from $196.00 to $182.00 and set an “overweight” rating for the company in a research note on Friday, April 11th. Wells Fargo & Company started coverage on Sarepta Therapeutics in a research report on Friday, April 11th. They set an “overweight” rating and a $115.00 price target on the stock. Needham & Company LLC cut their price objective on shares of Sarepta Therapeutics from $202.00 to $183.00 and set a “buy” rating for the company in a research report on Thursday, April 3rd. Finally, Royal Bank of Canada lowered shares of Sarepta Therapeutics from an “outperform” rating to a “sector perform” rating and decreased their target price for the stock from $161.00 to $87.00 in a report on Monday, March 31st. Six research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $157.95.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.